AR045408A1 - GENES AND POLYPEPTIDES RELATED TO CANCER OF HUMAN COLON - Google Patents
GENES AND POLYPEPTIDES RELATED TO CANCER OF HUMAN COLONInfo
- Publication number
- AR045408A1 AR045408A1 ARP030104390A ARP030104390A AR045408A1 AR 045408 A1 AR045408 A1 AR 045408A1 AR P030104390 A ARP030104390 A AR P030104390A AR P030104390 A ARP030104390 A AR P030104390A AR 045408 A1 AR045408 A1 AR 045408A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- seq
- polynucleotide
- amino acid
- acid sequence
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 21
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 21
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 21
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000001072 colon Anatomy 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 9
- 239000002157 polynucleotide Substances 0.000 abstract 9
- 102000040430 polynucleotide Human genes 0.000 abstract 9
- 108091033319 polynucleotide Proteins 0.000 abstract 9
- 150000001413 amino acids Chemical class 0.000 abstract 6
- 230000004071 biological effect Effects 0.000 abstract 6
- 239000002773 nucleotide Substances 0.000 abstract 5
- 125000003729 nucleotide group Chemical group 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Nuevo gen humano RNF 43 cuya expresión está marcadamente elevada en el cáncer colorrectal en comparación con los correspondientes tejidos no cancerosos. Los genes y los polipéptidos codificados por los genes se pueden usar, por ejemplo, en el diagnóstico de una enfermedad de células proliferativas, y como moléculas blanco para desarrollar fármacos contra la enfermedad. Reivindicación 1: Un polipéptido sustancialmente puro, caracterizado porque se selecciona del grupo formado por: a) un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2; b) un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2 en la cual se ha sustituido, suprimido, insertado y/o añadido uno o más aminoácidos y que posee una actividad biológica equivalente a una proteína que comprende la secuencia de aminoácidos de la SEQ ID N°: 2; y c) un polipéptido codificado por un polinucleótido que se hibridiza bajo condiciones severas con un polinucleótido que comprende la secuencia de nucleótidos de la SEQ ID N°: 1, donde el polipéptido posee una actividad biológica equivalente a un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2. Reivindicación 9: El polinucleótido antisentido de la cláusula 8, caracterizado porque se selecciona del grupo formado por nucleótidos que comprende la secuencia de nucleótidos de la SEQ ID N°: 10. Reivindicación 21: Una composición para tratar una enfermedad de células proliferativas, caracterizada porque dicha composición comprende una cantidad eficaz para uso farmacéutico de un anticuerpo contra un polipéptido seleccionado del grupo formado por: a) un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2; b) un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2 en la cual se ha sustituido, suprimido, insertado y/o añadido uno o más aminoácidos y que posee una actividad biológica equivalente de una proteína que comprende la secuencia de aminoácidos de la SEQ ID N°: 2; y c) un polipéptido codificado por un polinucleótido que se hibridiza bajo condiciones severas con un polinucleótido que comprende la secuencia de nucleótidos de la SEQ ID N°: 1, donde el polipéptido presenta una actividad biológica equivalente de un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2, como ingrediente activo y un vehículo aceptable para uso farmacéutico. Reivindicación 30: Un método para inducir inmunidad anti-tumoral, caracterizado porque dicho método comprende el paso de poner un polipéptido seleccionado del grupo formado por a)-c) en contacto con células presentadoras de antígenos, o introducir un polinucleótido que codifica el polipéptido o un vector que comprende el polinucleótido en células presentadoras de antígenos: a) un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2, o un fragmento del mismo; b) un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2 en la cual se ha sustituido, suprimido, insertado y/o añadido uno o más aminoácidos y que posee una actividad biológica equivalente de una proteína que comprende la secuencia de aminoácidos de la SEQ ID N°: 2, o un fragmento del mismo; c) un polipéptido codificado por un polinucleótido que se hibridiza bajo condiciones severas con un polinucleótido que comprende la secuencia de nucleótidos de la SEQ ID N°: 1, donde el polipéptido presenta una actividad biológica equivalente de un polipéptido que comprende la secuencia de aminoácidos de la SEQ ID N°: 2, o un fragmento del mismo.New human gene RNF 43 whose expression is markedly elevated in colorectal cancer compared to the corresponding non-cancerous tissues. Genes and polypeptides encoded by genes can be used, for example, in the diagnosis of a proliferative cell disease, and as white molecules to develop drugs against the disease. Claim 1: A substantially pure polypeptide, characterized in that it is selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID N °: 2; b) a polypeptide comprising the amino acid sequence of SEQ ID N °: 2 in which one or more amino acids have been substituted, deleted, inserted and / or added and possessing a biological activity equivalent to a protein comprising the sequence of amino acids of SEQ ID N °: 2; and c) a polypeptide encoded by a polynucleotide that hybridizes under severe conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID N °: 1, wherein the polypeptide possesses a biological activity equivalent to a polypeptide comprising the amino acid sequence of SEQ ID N °: 2. Claim 9: The antisense polynucleotide of clause 8, characterized in that it is selected from the group consisting of nucleotides comprising the nucleotide sequence of SEQ ID N °: 10. Claim 21: A composition for treating a proliferative cell disease, characterized in that said composition comprises an amount effective for pharmaceutical use of an antibody against a polypeptide selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID N °: 2; b) a polypeptide comprising the amino acid sequence of SEQ ID N °: 2 in which one or more amino acids have been substituted, deleted, inserted and / or added and possessing an equivalent biological activity of a protein comprising the sequence of amino acids of SEQ ID N °: 2; and c) a polypeptide encoded by a polynucleotide that hybridizes under severe conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID N °: 1, wherein the polypeptide exhibits an equivalent biological activity of a polypeptide comprising the amino acid sequence of SEQ ID N °: 2, as active ingredient and a vehicle acceptable for pharmaceutical use. Claim 30: A method for inducing anti-tumor immunity, characterized in that said method comprises the step of placing a polypeptide selected from the group consisting of a) -c) in contact with antigen presenting cells, or introducing a polynucleotide encoding the polypeptide or a vector comprising the polynucleotide in antigen presenting cells: a) a polypeptide comprising the amino acid sequence of SEQ ID N °: 2, or a fragment thereof; b) a polypeptide comprising the amino acid sequence of SEQ ID N °: 2 in which one or more amino acids have been substituted, deleted, inserted and / or added and possessing an equivalent biological activity of a protein comprising the sequence of amino acids of SEQ ID N °: 2, or a fragment thereof; c) a polypeptide encoded by a polynucleotide that hybridizes under severe conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID N °: 1, wherein the polypeptide exhibits an equivalent biological activity of a polypeptide comprising the amino acid sequence of SEQ ID N °: 2, or a fragment thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45101303P | 2003-02-28 | 2003-02-28 | |
| PCT/JP2003/007006 WO2003104275A2 (en) | 2002-06-06 | 2003-06-03 | Genes and polypeptides relating to human colon cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045408A1 true AR045408A1 (en) | 2005-10-26 |
Family
ID=42778403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104390A AR045408A1 (en) | 2003-02-28 | 2003-11-27 | GENES AND POLYPEPTIDES RELATED TO CANCER OF HUMAN COLON |
| ARP100102600 AR077577A2 (en) | 2003-02-28 | 2010-07-15 | POLIPEPTIDES RELATED TO CANCER OF HUMAN COLON, POLYUCLEOTIDES THAT CODE IT, VECTOR, USES AND PHARMACEUTICAL COMPOSITIONS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102600 AR077577A2 (en) | 2003-02-28 | 2010-07-15 | POLIPEPTIDES RELATED TO CANCER OF HUMAN COLON, POLYUCLEOTIDES THAT CODE IT, VECTOR, USES AND PHARMACEUTICAL COMPOSITIONS |
Country Status (2)
| Country | Link |
|---|---|
| AR (2) | AR045408A1 (en) |
| TW (1) | TWI324608B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI596109B (en) * | 2007-02-21 | 2017-08-21 | 腫瘤療法 科學股份有限公司 | Peptide vaccine for cancers exhibiting tumor-associated antigens |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| BRPI0923402A2 (en) | 2008-12-24 | 2015-08-04 | Oncotherapy Science Inc | C10rf59 peptides and vaccines including the same. |
-
2003
- 2003-11-24 TW TW092132870A patent/TWI324608B/en not_active IP Right Cessation
- 2003-11-27 AR ARP030104390A patent/AR045408A1/en active IP Right Grant
-
2010
- 2010-07-15 AR ARP100102600 patent/AR077577A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200502247A (en) | 2005-01-16 |
| AR077577A2 (en) | 2011-09-07 |
| TWI324608B (en) | 2010-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240408191A1 (en) | Nucleic acid vaccines | |
| AU2022206783A1 (en) | Nucleic acid products and methods of administration thereof | |
| ES2661500T3 (en) | HMGB1 variants and their uses | |
| EP1548032A4 (en) | KDR PEPTIDES AND VACCINES CONTAINING THEM | |
| ES3047691T3 (en) | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) | |
| KR20190071725A (en) | RNA-guided nucleic acid modification enzymes and methods for their use | |
| MY162056A (en) | Diagnosis and treatment of cancer using anti -ereg antibody | |
| CN107320719A (en) | HGH XTEN fusion proteins and its purposes in treatment growth hormone deficiency | |
| RU2006130791A (en) | GASTROINTESTINAL PROLIFERATIVE FACTOR AND ITS APPLICATIONS | |
| Pfankuche et al. | Reduced angiogenic gene expression in morbillivirus‐triggered oncolysis in a translational model for histiocytic sarcoma | |
| AR029814A1 (en) | MOLECULES MADE WITH CHORDIN 2 AND USES OF THE SAME | |
| CN114585384A (en) | Compositions and methods of using C/EBPa saRNA | |
| Chae et al. | TGF‐β1 overexpressing human MSCs generated using gene editing show robust therapeutic potential for treating collagen‐induced arthritis | |
| EP2182068A1 (en) | Use of bacteria for the sensing and killing of cancer cells | |
| Vervenne et al. | Lpp is involved in Wnt/PCP signaling and acts together with Scrib to mediate convergence and extension movements during zebrafish gastrulation | |
| AR045408A1 (en) | GENES AND POLYPEPTIDES RELATED TO CANCER OF HUMAN COLON | |
| US9567369B2 (en) | Method of treating metastatic cancer | |
| Yang et al. | Preconditioning of adipose‐derived stem cells by phosphodiesterase‐5 inhibition enhances therapeutic efficacy against diabetes‐induced erectile dysfunction | |
| Edinger et al. | Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF | |
| BRPI0910513B8 (en) | use of at least one polypeptide, method for detecting breast cancer and leukemia in vitro, and reagent for detecting breast cancer and leukemia | |
| JP2015203014A (en) | Spinal cord tissue targeting peptide and use thereof | |
| CN102808016A (en) | Applications of ARID1A gene and protein product encoded by the same | |
| KR20160015462A (en) | Peptide for promoting angiogenic activity and use thereof | |
| US11541101B1 (en) | LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol | |
| JP6830651B2 (en) | Peptides, polynucleotides, vectors, transformants, NFκB inhibitors, and therapeutic agents for NFκB-promoting diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration |